Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

PEP02

 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
A multicenter, open‐label, noncomparative, randomized phase II study (PEPCOL) was conducted to evaluate the efficacy and safety… Expand
Is this relevant?
2016
2016
BackgroundPEP02 (also known as MM-398, nal-IRI) is a novel nanoparticle formulation of irinotecan encapsulated in liposomes. The… Expand
  • table 1
  • table 2
  • table 3
  • table 4
  • figure 1
Is this relevant?
Highly Cited
2014
Highly Cited
2014
AbstractPurpose To define the dose-limiting toxicity (DLT), maximum tolerated dose (MTD) and pharmacokinetics (PK) of PEP02, a… Expand
  • table 1
  • table 2
  • table 3
  • table 4
  • figure 1
Is this relevant?
Highly Cited
2013
Highly Cited
2013
Background:PEP02, also known as MM-398, is a novel nanoliposomal irinotecan that has improved pharmacokinetics and tumour bio… Expand
  • table 1
  • table 2
  • figure 2
  • table 3
  • figure 3
Is this relevant?
Highly Cited
2013
Highly Cited
2013
BACKGROUND PEP02 is a novel highly stable liposomal nanocarrier formulation of irinotecan. This randomized phase II study… Expand
  • figure 1
  • table 1
  • table 2
  • figure 2
  • table 3
Is this relevant?
2012
2012
613 Background: PEP02 (MM-398) is a nanoliposomal formulation of irinotecan (CPT-11) that has improved pharmacokinetics (PK) and… Expand
Is this relevant?
2011
2011
  • A. Ko, M. Tempero, +6 authors L. Chen
  • Journal of clinical oncology : official journal…
  • 2011
  • Corpus ID: 36258059
237 Background: PEP02 is a novel nanoparticle liposome formulation of irinotecan (CPT-11) that has improved pharmacokinetics and… Expand
Is this relevant?
2011
2011
6 Background: PEP02 is a novel nanoparticle liposome formulation of irinotecan (CPT-11). In phase I studies, PEP02 has improved… Expand
Is this relevant?
2010
2010
e13024 Background: PEP02 is a novel nanoparticle liposome formulation of irinotecan (CPT-11) that has improved PK and tumor… Expand
Is this relevant?
2008
2008
2565 Background: PEP02 is a novel nanoparticle liposome formulation of irinotecan aiming to enhance tumor localization and… Expand
Is this relevant?